Ahmed Elsherbiny1, Matthew Tricomi2, Digant Bhatt3, Hari Kumar Dandapantula4,5. 1. Hospital Medicine, Ashtabula County Medical Center, Ashtabula, OH, USA. 2. Clinical Pharmacy, Ashtabula County Medical Center, Ashtabula, OH, USA. 3. Canton Medical Education Foundation, Canton, OH, USA. 4. Heart and Vascular Institute, Ashtabula County Medical Center, Cleveland Clinic Foundation, Cleveland, OH, USA. harikumar7@yahoo.com. 5. Department of Cardiovascular Medicine, Cleveland Clinic Heart & Vascular Institute, Cleveland, OH, USA. harikumar7@yahoo.com.
Abstract
PURPOSE OF REVIEW: According to an Endocrine Society Clinical Practice Guideline published in June 2010, testosterone replacement therapy (TRT) should be administered only to men who are hypogonadal with documented low testosterone level on two morning measurements. This recommendation was based on previous studies that did not show an increased risk in cardiovascular events with TRT. In contrast, recent studies did show an increased risk which prompted the FDA to investigate further. RECENT FINDINGS: Multiple studies suggested an increased risk in cardiovascular events among groups of men prescribed TRT. There is recent evidence that TRT can be associated with higher cardiovascular risks, while these risks are still not well established, and more well-designed trials are needed. Physicians should always be cautious when prescribing TRT to their patients. Potential risks should be discussed with each patient, and TRT requires regular monitoring to help minimize side effects.
PURPOSE OF REVIEW: According to an Endocrine Society Clinical Practice Guideline published in June 2010, testosterone replacement therapy (TRT) should be administered only to men who are hypogonadal with documented low testosterone level on two morning measurements. This recommendation was based on previous studies that did not show an increased risk in cardiovascular events with TRT. In contrast, recent studies did show an increased risk which prompted the FDA to investigate further. RECENT FINDINGS: Multiple studies suggested an increased risk in cardiovascular events among groups of men prescribed TRT. There is recent evidence that TRT can be associated with higher cardiovascular risks, while these risks are still not well established, and more well-designed trials are needed. Physicians should always be cautious when prescribing TRT to their patients. Potential risks should be discussed with each patient, and TRT requires regular monitoring to help minimize side effects.
Authors: Christina Wang; Glenn Cunningham; Adrian Dobs; Ali Iranmanesh; Alvin M Matsumoto; Peter J Snyder; Thomas Weber; Nancy Berman; Laura Hull; Ronald S Swerdloff Journal: J Clin Endocrinol Metab Date: 2004-05 Impact factor: 5.958
Authors: Kay-Tee Khaw; Mitch Dowsett; Elizabeth Folkerd; Sheila Bingham; Nicholas Wareham; Robert Luben; Ailsa Welch; Nicholas Day Journal: Circulation Date: 2007-11-26 Impact factor: 29.690
Authors: Jacques Baillargeon; Randall J Urban; Yong-Fang Kuo; Kenneth J Ottenbacher; Mukaila A Raji; Fei Du; Yu-Li Lin; James S Goodwin Journal: Ann Pharmacother Date: 2014-07-02 Impact factor: 3.154
Authors: Abraham Morgentaler; Michael Zitzmann; Abdulmaged M Traish; Anthony W Fox; T Hugh Jones; Mario Maggi; Stefan Arver; Antonio Aversa; Juliana C N Chan; Adrian S Dobs; Geoffrey I Hackett; Wayne J Hellstrom; Peter Lim; Bruno Lunenfeld; George Mskhalaya; Claude C Schulman; Luiz O Torres Journal: Mayo Clin Proc Date: 2016-06-21 Impact factor: 7.616
Authors: T Hugh Jones; Stefan Arver; Hermann M Behre; Jacques Buvat; Eric Meuleman; Ignacio Moncada; Antonio Martin Morales; Maurizio Volterrani; Ann Yellowlees; Julian D Howell; Kevin S Channer Journal: Diabetes Care Date: 2011-03-08 Impact factor: 19.112